• 5795 Citations
  • 32 h-Index
1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 5795 Citations
  • 32 h-Index
  • 118 Article
  • 6 Review article
  • 5 Letter
  • 1 Comment/debate
Filter
Article
2012

Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

Trask, P. C., Cella, D., Besson, N., Kelly, V., Masszi, T. & Kim, D. W., ápr. 1 2012, In : Leukemia Research. 36, 4, p. 438-442 5 p.

Research output: Article

27 Citations (Scopus)
64 Citations (Scopus)

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: Safety and efficacy data in a series of 21 patients from Europe and the USA

Douglas, K. W., Parker, A. N., Hayden, P. J., Rahemtulla, A., D'Addio, A., Lemoli, R. M., Rao, K., Maris, M., Pagliuca, A., Uberti, J., Scheid, C., Noppeney, R., Cook, G., Bokhari, S. W., Worel, N., Mikala, G., Masszi, T., Taylor, R. & Treisman, J., jan. 1 2012, In : Bone Marrow Transplantation. 47, 1, p. 18-23 6 p.

Research output: Article

15 Citations (Scopus)

Superiority of the triple combination of bortezomib-thalidomide- dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The MMVAR/IFM 2005-04 randomized phase III trial from the chronic leukemia working party of the European Group for blood and marrow transplantation

Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A., Milone, G., Doyen, C., Pegourie, B., Hajek, R., Casassus, P., Kolb, B., Chaleteix, C., Hertenstein, B., Onida, F., Ludwig, H. & 10 others, Ketterer, N., Koenecke, C., Van Os, M., Mohty, M., Cakana, A., Gorin, N. C., De Witte, T., Harousseau, J. L., Morris, C. & Gahrton, G., júl. 10 2012, In : Journal of Clinical Oncology. 30, 20, p. 2475-2482 8 p.

Research output: Article

168 Citations (Scopus)
2013

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: Comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus cy as conditioning regimen-A report from the acute leukemia working party of theeuropean group for blood and marrow transplantation

Nagler, A., Rocha, V., Labopin, M., Unal, A., Ben Othman, T., Campos, A., Volin, L., Poire, X., Aljurf, M., Masszi, T., Socie, G., Sengelov, H., Michallet, M., Passweg, J., Veelken, H., Yakoub-Agha, I., Shimoni, A. & Mohty, M., okt. 1 2013, In : Journal of Clinical Oncology. 31, 28, p. 3549-3556 8 p.

Research output: Article

82 Citations (Scopus)

Quality of life and its socio-demographic and psychological determinants after bone marrow transplantation

Janicsák, H., Masszi, T., Reményi, P., Ungvari, G. S. & Gazdag, G., aug. 1 2013, In : European journal of haematology. 91, 2, p. 135-140 6 p.

Research output: Article

9 Citations (Scopus)

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

Ludwig, H., Viterbo, L., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M. B., Esteves, G., Stoppa, A. M., Robinson, D., Ricci, D., Cakana, A., Enny, C., Feng, H., Van De Velde, H. & Harousseau, J. L., jan. 10 2013, In : Journal of Clinical Oncology. 31, 2, p. 247-255 9 p.

Research output: Article

59 Citations (Scopus)
5 Citations (Scopus)

Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia

Koszarska, M., Bors, A., Feczko, A., Meggyesi, N., Batai, A., Csomor, J., Adam, E., Kozma, A., Orban, T. I., Lovas, N., Sipos, A., Karaszi, E., Dolgos, J., Fekete, S., Reichardt, J., Lehoczky, E., Masszi, T., Tordai, A. & Andrikovics, H., máj. 1 2013, In : Leukemia and Lymphoma. 54, 5, p. 1028-1035 8 p.

Research output: Article

19 Citations (Scopus)
2014

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Gambacorti-Passerini, C., Brümmendorf, T. H., Kim, D. W., Turkina, A. G., Masszi, T., Assouline, S., Durrant, S., Kantarjian, H. M., Khoury, H. J., Zaritskey, A., Shen, Z. X., Jin, J., Vellenga, E., Pasquini, R., Mathews, V., Cervantes, F., Besson, N., Turnbull, K., Leip, E., Kelly, V. & 1 others, Cortes, J. E., júl. 2014, In : American Journal of Hematology. 89, 7, p. 732-742 11 p.

Research output: Article

66 Citations (Scopus)

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Andrikovics, H., Krahling, T., Balassa, K., Halm, G., Bors, A., Koszarska, M., Batai, A., Dolgos, J., Csomor, J., Egyed, M., Sipos, A., Remenyi, P., Tordai, A. & Masszi, T., júl. 1 2014, In : Haematologica. 99, 7, p. 1184-1190 7 p.

Research output: Article

60 Citations (Scopus)

Komplex molekuláris genetikai vizsgálati algoritmus myeloproliferativ neoplasiák diagnosztikájában

Krhling, T., Balassa, K., Meggyesi, N., Bors, A., Csomor, J., Bátai, Á., Halm, G., Egyed, M., Fekete, S., Reményi, P., Masszi, T., Tordai, A. & Andrikovics, H., dec. 1 2014, In : Orvosi hetilap. 155, 52, p. 2074-2081 8 p.

Research output: Article

4 Citations (Scopus)

Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort

Koszarska, M., Meggyesi, N., Bors, A., Batai, A., Csacsovszki, O., Lehoczky, E., Adam, E., Kozma, A., Lovas, N., Sipos, A., Krahling, T., Dolgos, J., Remenyi, P., Fekete, S., Masszi, T., Tordai, A. & Andrikovics, H., júl. 2014, In : Leukemia and Lymphoma. 55, 7, p. 1510-1517 8 p.

Research output: Article

4 Citations (Scopus)

Mennyit vár ma Magyarországon egy myelomás beteg a diagnózisig?

Varga, G., Mikala, G., Andrikovics, H. & Masszi, T., szept. 1 2014, In : Orvosi hetilap. 155, 39, p. 1538-1543 6 p.

Research output: Article

2 Citations (Scopus)

Peripheral Blood Stem Cell Mobilization and Engraftment after Autologous Stem Cell Transplantation with Biosimilar rhG-CSF

Reményi, P., Gopcsa, L., Marton, I., Réti, M., Mikala, G., Pető, M., Barta, A., Bátai, Á., Farkas, Z., Borbényi, Z., Csukly, Z., Bodó, I., Fábián, J., Király, Á., Lengyel, L., Piukovics, K., Torbágyi, É. & Masszi, T., ápr. 1 2014, In : Advances in Therapy. 31, 4, p. 451-460 10 p.

Research output: Article

19 Citations (Scopus)
31 Citations (Scopus)
2015

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Špička, I., Maiolino, A., Suvorov, A., Bladé, J., Samoylova, O., Puchalski, T. A., Reddy, M., Bandekar, R., van de Velde, H., Xie, H. & Rossi, J. F., jan. 1 2015, In : American Journal of Hematology. 90, 1, p. 42-49 8 p.

Research output: Article

71 Citations (Scopus)

Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study

O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., Bhat, G., Choi, M. R., Walewski, J., Savage, K., Foss, F., Allen, L. F. & Shustov, A., aug. 10 2015, In : Journal of Clinical Oncology. 33, 23, p. 2492-2499 8 p.

Research output: Article

177 Citations (Scopus)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Ludwig, H., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M. B., Esteves, G., Stoppa, A. M., Robinson, D., Chaturvedi, S., Ataman, O., Enny, C., Feng, H., van de Velde, H. & Viterbo, L., nov. 2015, In : British Journal of Haematology. 171, 3, p. 344-354 11 p.

Research output: Article

18 Citations (Scopus)

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., Osmanov, D., Bachanova, V., Sweetenham, J., Sureda, A., Huebner, D., Sievers, E. L., Chi, A., Larsen, E. K., Hunder, N. N. & Walewski, J., máj. 9 2015, In : The Lancet. 385, 9980, p. 1853-1862 10 p.

Research output: Article

323 Citations (Scopus)

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

ASPIRE Investigators, jan. 8 2015, In : New England Journal of Medicine. 372, 2, p. 142-152 11 p.

Research output: Article

630 Citations (Scopus)

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

Varga, G., Mikala, G., Andrikovics, H., Koszarska, M., Balassa, K., Ádám, E., Kozma, A., Tordai, A. & Masszi, T., márc. 1 2015, In : British Journal of Haematology. 168, 5, p. 679-688 10 p.

Research output: Article

8 Citations (Scopus)

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

Khoury, H. J., Cortes, J., Baccarani, M., Wetzler, M., Masszi, T., Digumarti, R., Craig, A., Benichou, A. C. & Akard, L., jan. 1 2015, In : Leukemia and Lymphoma. 56, 1, p. 120-127 8 p.

Research output: Article

14 Citations (Scopus)

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia

Stone, R. M., Mazzola, E., Neuberg, D., Allen, S. L., Pigneux, A., Stuart, R. K., Wetzler, M., Rizzieri, D., Erba, H. P., Damon, L., Jang, J. H., Tallman, M. S., Warzocha, K., Masszi, T., Sekeres, M. A., Egyed, M., Horst, H. A., Selleslag, D., Solomon, S. R., Venugopal, P. & 2 others, Lundberg, A. S. & Powell, B., márc. 20 2015, In : Journal of Clinical Oncology. 33, 11, p. 1252-1257 6 p.

Research output: Article

34 Citations (Scopus)

Ruxolitinib versus standard therapy for the treatment of polycythemia vera

Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., He, S., Jones, M. M., Garrett, W., Li, J., Pirron, U., Habr, D. & Verstovsek, S., jan. 1 2015, In : New England Journal of Medicine. 372, 5, p. 426-435 10 p.

Research output: Article

272 Citations (Scopus)

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

Pardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., Drummond, M. W., Jurgutis, M., Kuliczkowski, K., Gheorghita, E., Passamonti, F., Neumann, F., Patki, A., Gao, G. & Tefferi, A., aug. 1 2015, In : JAMA oncology. 1, 5, p. 643-651 9 p.

Research output: Article

96 Citations (Scopus)

The potential role of HLA-DRB1∗11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy

Balassa, K., Andrikovics, H., Remenyi, P., Batai, A., Bors, A., Kiss, K. P., Szilvasi, A., Rajczy, K., Inotai, D., Gopcsa, L., Lengyel, L., Barta, A., Reti, M., Tordai, A. & Masszi, T., okt. 1 2015, In : Bone Marrow Transplantation. 50, 10, p. 1321-1325 5 p.

Research output: Article

11 Citations (Scopus)
2016

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A., Rosiñol, L., Nagler, A., Yong, K. L., Oriol, A., Minarik, J., Pour, L., Dimopoulos, M. A., Maisnar, V., Rossi, D., Kasparu, H., van Droogenbroeck, J., Yehuda, D. B., Hardan, I., Jenner, M., Calbecka, M., Dávid, M. & 12 others, de la Rubia, J., Drach, J., Gasztonyi, Z., Górnik, S., Leleu, X., Munder, M., Offidani, M., Zojer, N., Rajangam, K., Chang, Y. L., San-Miguel, J. F. & Ludwig, H., júl. 15 2016, (Accepted/In press) In : Leukemia.

Research output: Article

59 Citations (Scopus)

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A. & 11 others, Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S. & Chng, W. J., jan. 1 2016, In : The Lancet Oncology. 17, 1, p. 27-38 12 p.

Research output: Article

370 Citations (Scopus)

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., Špička, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V., Mihaylov, G., Maisnar, V., Mateos, M. V., Wang, M., Niesvizky, R., Oriol, A., Jakubowiak, A., Minarik, J., Palumbo, A., Bensinger, W., Kukreti, V. & 4 others, Ben-Yehuda, D., Stewart, A. K., Obreja, M. & Moreau, P., szept. 1 2016, In : Blood. 128, 9, p. 1174-1180 7 p.

Research output: Article

59 Citations (Scopus)

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

Mesa, R., Verstovsek, S., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Zhen, H., Jones, M. M., Parasuraman, S., Li, J., Côté, I., Habr, D. & Vannucchi, A. M., aug. 1 2016, In : European journal of haematology. 97, 2, p. 192-200 9 p.

Research output: Article

23 Citations (Scopus)

Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100

Krahling, T., Balassa, K., Kiss, K. P., Bors, A., Batai, A., Halm, G., Egyed, M., Fekete, S., Remenyi, P., Masszi, T., Tordai, A. & Andrikovics, H., jan. 1 2016, In : Cancer Epidemiology Biomarkers and Prevention. 25, 1, p. 98-104 7 p.

Research output: Article

14 Citations (Scopus)

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., Mark, T. M., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A. & Sonneveld, P., aug. 25 2016, In : New England Journal of Medicine. 375, 8, p. 754-766 13 p.

Research output: Article

505 Citations (Scopus)

Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years

Remenyi, P., Varga, G., Mikala, G., Reti, M., Gopcsa, L., Batai, A., Csukly, Z., Lengyel, L., Torbagyi, E., Barta, A., Fabian, J., Levai, D., Szombath, G., Andrikovics, H. & Masszi, T., jan. 1 2016, In : Transplantation Proceedings. 48, 1, p. 177-184 8 p.

Research output: Article

7 Citations (Scopus)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the European ENEST1st study

Hochhaus, A., Rosti, G., Cross, N. C. P., Steegmann, J. L., Le Coutre, P., Ossenkoppele, G., Petrov, L., Masszi, T., Hellmann, A., Griskevicius, L., Wiktor-Jedrzejczak, W., Rea, D., Coriu, D., Brümmendorf, T. H., Porkka, K., Saglio, G., Gastl, G., Müller, M. C., Schuld, P., Di Matteo, P. & 5 others, Pellegrino, A., Dezzani, L., Mahon, F. X., Baccarani, M. & Giles, F. J., jan. 1 2016, In : Leukemia. 30, 1, p. 57-64 8 p.

Research output: Article

60 Citations (Scopus)

Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma

Stewart, A. K., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Buchanan, J., Cocks, K., Yang, X., Xing, B., Zojwalla, N., Tonda, M., Moreau, P. & Palumbo, A., nov. 10 2016, In : Journal of Clinical Oncology. 34, 32, p. 3921-3930 10 p.

Research output: Article

33 Citations (Scopus)

Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

Mátrai, Z., Andrikovics, H., Szilvási, A., Bors, A., Kozma, A., Ádám, E., Halm, G., Karászi, É., Tordai, A. & Masszi, T., okt. 18 2016, (Accepted/In press) In : Pathology and Oncology Research. p. 1-7 7 p.

Research output: Article

3 Citations (Scopus)

Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma

TOURMALINE-MM1 Study Group, ápr. 28 2016, In : New England Journal of Medicine. 374, 17, p. 1621-1634 14 p.

Research output: Article

436 Citations (Scopus)

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

Ramsey, S. D., Nademanee, A., Masszi, T., Holowiecki, J., Abidi, M., Chen, A., Stiff, P., Viviani, S., Sweetenham, J. W., Radford, J., Zhu, Y., Bonthapally, V., Thomas, E., Richhariya, A., Hunder, N. N., Walewski, J. & Moskowitz, C. H., 2016, (Accepted/In press) In : British Journal of Haematology.

Research output: Article

10 Citations (Scopus)

Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

Balassa, K., Krahling, T., Remenyi, P., Batai, A., Bors, A., Kiss, K. P., Torbagyi, E., Gopcsa, L., Lengyel, L., Barta, A., Varga, G., Tordai, A., Masszi, T. & Andrikovics, H., júl. 7 2016, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-8 8 p.

Research output: Article

4 Citations (Scopus)

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation

Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J. H., Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A. & 12 others, NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F. & Carreras, E., júl. 1 2016, In : Bone Marrow Transplantation. 51, 7, p. 906-912 7 p.

Research output: Article

102 Citations (Scopus)

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Verstovsek, S., Vannucchi, A. M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Kirito, K., Besses, C., Hino, M., Moiraghi, B., Miller, C. B., Cazzola, M., Rosti, V., Blau, I., Mesa, R., Jones, M. M., Zhen, H. & 4 others, Li, J., Francillard, N., Habr, D. & Kiladjian, J. J., jan. 1 2016, In : Haematologica. 101, 7, p. 821-829 9 p.

Research output: Article

72 Citations (Scopus)
2017

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

Dimopoulos, M. A., Stewart, A. K., Masszi, T., Spicka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Ro, S., Aggarwal, S., Moreau, P. & Palumbo, A., jan. 1 2017, In : Blood Cancer Journal. 7, 4, e554.

Research output: Article

23 Citations (Scopus)

Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Mateos, M. V., Masszi, T., Grzasko, N., Hansson, M., Sandhu, I., Pour, L., Viterbo, L., Jackson, S. R., Stoppa, A. M., Gimsing, P., Hamadani, M., Borsaru, G., Berg, D., Lin, J., Di Bacco, A., Van De Velde, H., Richardson, P. G. & Moreau, P., szept. 30 2017, In : Haematologica. 102, 10, p. 1767-1775 9 p.

Research output: Article

20 Citations (Scopus)

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Avet-Loiseau, H., Bahlis, N. J., Chng, W. J., Masszi, T., Viterbo, L., Pour, L., Ganly, P., Palumbo, A., Cavo, M., Langer, C., Pluta, A., Nagler, A., Kumar, S., Ben-Yehuda, D., Rajkumar, S. V., San-Miguel, J., Berg, D., Lin, J., Van De Velde, H., Esseltine, D. L. & 3 others, di Bacco, A., Moreau, P. & Richardson, P. G., dec. 14 2017, In : Blood. 130, 24, p. 2610-2618 9 p.

Research output: Article

34 Citations (Scopus)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

Kumar, S., Moreau, P., Hari, P., Mateos, M. V., Ludwig, H., Shustik, C., Masszi, T., Spencer, A., Hájek, R., Romeril, K., Avivi, I., Liberati, A. M., Minnema, M. C., Einsele, H., Lonial, S., Berg, D., Lin, J., Gupta, N., Esseltine, D. L. & Richardson, P. G., aug. 2017, In : British Journal of Haematology. 178, 4, p. 571-582 12 p.

Research output: Article

27 Citations (Scopus)

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma

Varga, G., Mikala, G., Kiss, K. P., Kosóczki, É., Szabó, E., Meggyesi, N., Balassa, K., Kövy, P., Tegze, B., Szombath, G., Tordai, A., Andrikovics, H., Homolya, L. & Masszi, T., nov. 1 2017, In : Clinical Lymphoma, Myeloma and Leukemia. 17, 11, p. 734-742 9 p.

Research output: Article

1 Citation (Scopus)
2018

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT

Giebel, S., Labopin, M., Potter, M., Poiré, X., Sengeloev, H., Socié, G., Huynh, A., Afanasyev, B. V., Schanz, U., Ringden, O., Kalhs, P., Beelen, D. W., Campos, A. M., Masszi, T., Canaani, J., Mohty, M. & Nagler, A., jún. 1 2018, In : European Journal of Cancer. 96, p. 73-81 9 p.

Research output: Article

7 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., máj. 1 2018, In : Journal of cancer research and clinical oncology. 144, 5, p. 945-954 10 p.

Research output: Article

32 Citations (Scopus)